Dr. Reddy’s Laboratories Ltd (NYSE:RDY) Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. reduced its stake in shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) by 6.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,711,236 shares of the company’s stock after selling 727,672 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Dr. Reddy’s Laboratories were worth $141,281,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Rhumbline Advisers grew its position in Dr. Reddy’s Laboratories by 458.0% in the fourth quarter. Rhumbline Advisers now owns 430,062 shares of the company’s stock valued at $6,791,000 after acquiring an additional 352,994 shares in the last quarter. Allworth Financial LP lifted its position in shares of Dr. Reddy’s Laboratories by 447.8% during the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock worth $41,000 after purchasing an additional 2,230 shares in the last quarter. Ieq Capital LLC boosted its stake in shares of Dr. Reddy’s Laboratories by 444.7% in the fourth quarter. Ieq Capital LLC now owns 20,753 shares of the company’s stock valued at $328,000 after purchasing an additional 16,943 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Dr. Reddy’s Laboratories by 271.5% in the fourth quarter. Bank of New York Mellon Corp now owns 82,006 shares of the company’s stock valued at $1,295,000 after purchasing an additional 59,930 shares during the period. Finally, QRG Capital Management Inc. grew its holdings in Dr. Reddy’s Laboratories by 379.0% during the 4th quarter. QRG Capital Management Inc. now owns 45,283 shares of the company’s stock valued at $715,000 after purchasing an additional 35,829 shares in the last quarter. 3.85% of the stock is owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Stock Down 0.6%

RDY stock opened at $15.50 on Thursday. The company has a current ratio of 1.92, a quick ratio of 1.37 and a debt-to-equity ratio of 0.02. The firm has a 50 day simple moving average of $14.54 and a 200-day simple moving average of $14.16. The company has a market capitalization of $12.94 billion, a P/E ratio of 23.48, a PEG ratio of 5.51 and a beta of 0.33. Dr. Reddy’s Laboratories Ltd has a twelve month low of $12.26 and a twelve month high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Friday, May 9th. The company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.02. The firm had revenue of $996.17 million for the quarter, compared to the consensus estimate of $83.70 billion. Dr. Reddy’s Laboratories had a net margin of 17.38% and a return on equity of 17.98%. On average, equities research analysts predict that Dr. Reddy’s Laboratories Ltd will post 0.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RDY has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. HSBC upgraded Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating and boosted their price target for the stock from $14.44 to $16.90 in a research note on Thursday, June 5th. Finally, Hsbc Global Res upgraded Dr. Reddy’s Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 5th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $16.95.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.